All In Biotech

Drug Trial Radar · NCT04042844

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

A Phase 2, Double-Blind, Controlled, Randomized Study to Evaluate the Safety and Preliminary Efficacy of a Single Dose Intradiscal Injection of BRTX-100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Last checked: Nov 19, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

Jun 30, 2022

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
BioRestorative TherapiesIndustry
Sponsor type
Industry
First posted
Aug 2, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, controlled, randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic measures such as computed tomography (CT), magnetic resonance imaging (MRI), plain film, myelography, discography, or other acceptable means.

Conditions

  • Lumbar Disc Disease

Interventions

  • BRTX-100Biological

    Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous platelet lysate.

  • SalineDrug

    Sodium Chloride (0.9%) intravenous infusion preparation is a sterile and non-pyrogenic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety MeasuresTime frame: Baseline through Week 104 / Early Termination
  2. Primary Efficacy MeasuresTime frame: Baseline through Week 52

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama Clinical Therapeutics, LLC

    Birmingham, Alabama · Withdrawn

  • Source Healthcare

    Santa Monica, California · Recruiting

  • Boomerang Healthcare

    Walnut Creek, California · Recruiting

  • Denver Back Pain Specialists, LLC

    Greenwood Village, Colorado · Recruiting

  • Cantor Spine Institute

    Fort Lauderdale, Florida · Withdrawn

  • Coastal Health

    Jacksonville, Florida · Recruiting

  • Pain Relief Centers

    St. Petersburg, Florida · Recruiting

  • Tampa Pain Relief Center

    Tampa, Florida · Recruiting

  • Florida Pain Relief Center

    Tampa, Florida · Recruiting

  • Conquest Research

    Winter Park, Florida · Recruiting

  • Northwell Health

    New York, New York · Recruiting

  • The Center of Clinical Research, LLC

    Winston-Salem, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Clinical Investigations LLC

    Edmond, Oklahoma · Withdrawn

  • Coastal Carolina Research Center

    North Charleston, South Carolina · Withdrawn

  • Science Connections

    Austin, Texas · Recruiting

  • NCP Center for Clinical Research and Innovation

    Houston, Texas · Recruiting

  • Precision Spine Care

    Tyler, Texas · Withdrawn

  • Virginia iSpine Physicians

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.